Articles with public access mandates - Toby A. EyreLearn more
Not available anywhere: 14
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
AR Mato, NN Shah, W Jurczak, CY Cheah, JM Pagel, JA Woyach, ...
The Lancet 397 (10277), 892-901, 2021
Mandates: US National Institutes of Health
Diagnostic dilemmas of high‐grade transformation (Richter's syndrome) of chronic lymphocytic leukaemia: results of the phase II National Cancer Research Institute CHOP‐OR …
EJ Soilleux, A Wotherspoon, TA Eyre, R Clifford, M Cabes, AH Schuh
Histopathology 69 (6), 1066-1076, 2016
Mandates: US National Institutes of Health, National Institute for Health Research, UK
Management and controversies of classical Hodgkin lymphoma in pregnancy
TA Eyre, IJ Lau, L Mackillop, GP Collins
British Journal of Haematology 169 (5), 613-630, 2015
Mandates: National Institute for Health Research, UK
Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and …
N Martinez‐Calle, E Poynton, A Alchawaf, S Kassam, M Horan, M Rafferty, ...
British journal of haematology 190 (3), 394-404, 2020
Mandates: National Institute for Health Research, UK
Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia
T Eyre, CJ Schwab, R Kinstrie, AK McGuire, J Strefford, A Peniket, A Mead, ...
Blood, The Journal of the American Society of Hematology 120 (22), 4441-4443, 2012
Mandates: US National Institutes of Health, Cancer Research UK
A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL
TA Eyre, C Hildyard, A Hamblin, AS Ali, A Houlton, L Hopkins, D Royston, ...
Hematological oncology 37 (4), 352-359, 2019
Mandates: Blood Cancer UK, Cancer Research UK, National Institute for Health Research, UK
Results of a multicentre UK‐wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma
TA Eyre, KM Linton, P Rohman, J Kothari, K Cwynarski, K Ardeshna, ...
British journal of haematology 173 (6), 896-904, 2016
Mandates: National Institute for Health Research, UK
High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom
S Kassam, E Chernucha, A O’Neill, C Hemmaway, T Cummins, S Montoto, ...
Bone marrow transplantation 52 (9), 1268-1272, 2017
Mandates: National Institute for Health Research, UK
Emerging therapies for the management of Richter transformation
E Smyth, TA Eyre, CY Cheah
Journal of Clinical Oncology 41 (2), 395-409, 2023
Mandates: National Institute for Health Research, UK
Ncri petrea trial: a phase 3 evaluation of pet‐guided, response‐adapted therapy in patients with previously untreated, advanced‐stage, high‐tumour‐burden follicular lymphoma
AR Pettitt, S Barrington, N Kalakonda, UT Khan, R Jackson, S Carruthers, ...
Hematological Oncology 37, 67-68, 2019
Mandates: UK Medical Research Council
Bone health and glucocorticoid‐containing lymphoma therapy—a review of risk factors and preventative measures
TA Eyre, P Jensen, S Booth, TC El‐Galaly
British Journal of Haematology 198 (3), 431-442, 2022
Mandates: National Institute for Health Research, UK
How I manage mantle cell lymphoma: indolent versus aggressive disease
MR Wilson, A Barrett, CY Cheah, TA Eyre
British Journal of Haematology 201 (2), 185-198, 2023
Mandates: National Institute for Health Research, UK
Venetoclax induces deep and durable minimal residual disease‐negative remission in high‐risk TP53 disrupted B prolymphocytic leukaemia
LY Chen, TA Eyre
European Journal of Haematology 109 (5), 590-592, 2022
Mandates: National Institute for Health Research, UK
Efficacy and tolerability of VCD chemotherapy in a UK real‐world dataset of elderly transplant‐ineligible newly diagnosed myeloma patients
A Rampotas, F Djebbari, F Panitsas, C Lees, I Tsagkaraki, AR Gomes, ...
European Journal of Haematology 106 (4), 563-573, 2021
Mandates: National Institute for Health Research, UK
Available somewhere: 72
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
AR Mato, LE Roeker, N Lamanna, JN Allan, L Leslie, JM Pagel, K Patel, ...
Blood, The Journal of the American Society of Hematology 136 (10), 1134-1143, 2020
Mandates: US National Institutes of Health, National Institute for Health Research, UK
Real-world experience with caplacizumab in the management of acute TTP
T Dutt, RJ Shaw, M Stubbs, J Yong, B Bailiff, T Cranfield, MP Crowley, ...
Blood, The Journal of the American Society of Hematology 137 (13), 1731-1740, 2021
Mandates: National Institute for Health Research, UK
Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy
TA Eyre, HS Walter, S Iyengar, G Follows, M Cross, CP Fox, A Hodson, ...
Haematologica 104 (2), e68, 2019
Mandates: Cancer Research UK, UK Medical Research Council
Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy
AR Mato, LE Roeker, R Jacobs, BT Hill, N Lamanna, D Brander, ...
Clinical Cancer Research 26 (14), 3589-3596, 2020
Mandates: US National Institutes of Health, National Institute for Health Research, UK
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
UKCLL Forum
haematologica 101 (12), 1563, 2016
Mandates: Cancer Research UK
Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice
LE Roeker, CP Fox, TA Eyre, DM Brander, JN Allan, SJ Schuster, ...
Clinical Cancer Research 25 (14), 4264-4270, 2019
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program